Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/trf.16105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Microangiopathic Hemolytic Anemia as the Initial Presentation of Metastatic Signet-Ring Cell Carcinoma of the Colon: A Case Report.
Cureus
December 2024
Internal Medicine, Hurley Medical Center, Flint, USA.
Microangiopathic hemolytic anemia (MAHA) is a condition characterized by intravascular fragmentation of red blood cells, leading to the characteristic finding of schistocytes on a peripheral blood smear. The differential diagnoses of MAHA include thrombotic thrombocytopenic purpura (TTP), hemolytic-uremic syndrome (HUS), disseminated intravascular coagulation (DIC), idiopathic thrombocytopenic purpura (ITP), infections, malignancies, and solid organ transplantation. The commonly associated malignancies with MAHA are gastric, breast, prostate, lung, and lymphoma.
View Article and Find Full Text PDFVitamin B12 Deficiency in Thrombotic Thrombocytopenic Purpura-Like Cases.
Eur J Case Rep Intern Med
September 2024
Hematology and Oncology, University Cancer & Blood Center, Athens, USA.
Article Synopsis
- Thrombotic microangiopathies (TMA) involve a combination of hemolytic anemia, low platelet counts, and organ damage typically stemming from endothelial damage, but vitamin B12 deficiency can mimic this condition.
- A 60-year-old woman presented with signs of severe illness, leading to a high-risk diagnosis of thrombotic thrombocytopenic purpura (TTP), but was later found to have a significant vitamin B12 deficiency, which explained her symptoms.
- This case emphasizes that vitamin B12 deficiency can present like TTP, and clinicians should consider it as a potential cause of microangiopathic hemolytic anemia when specific lab results indicate low B12 levels and low reticulocyte counts, enabling
A Rare Intersection: Managing Thrombotic Thrombocytopenic Purpura in the Context of Dengue Fever.
Cureus
September 2024
Internal Medicine, Al Qassimi Hospital, Sharjah, ARE.
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening condition that can lead to severe morbidity and mortality if untreated. This case report discusses a 31-year-old male with dengue fever who developed TTP, resulting in fatality despite timely diagnosis and comprehensive treatment. The patient presented with worsening symptoms, including body aches, gastrointestinal bleeding, and neurological issues.
View Article and Find Full Text PDFRefining the standard of care in immune thrombotic thrombocytopenic purpura.
Clin Adv Hematol Oncol
October 2024
Division of Hematology and Medical Oncology, NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York, New York.
Article Synopsis
- Acute immune thrombotic thrombocytopenic purpura (iTTP) is a serious condition that requires immediate medical attention and tests to see how it's affecting the blood.
- Patients usually start treatment with plasma exchange (PE) and may also receive medications like glucocorticoids, rituximab, and caplacizumab to help improve their condition.
- A study showed that using caplacizumab can reduce repeated episodes and speed up recovery, but there are some risks, like bleeding, which mostly get better on their own.
Caplacizumab as an add-on therapy in a 7-year-old girl with exacerbated immune-mediated thrombotic thrombocytopenic purpura, a case report and literature review.
Front Pediatr
August 2024
Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent Medicine, Geneva University Hospital, Geneva, Switzerland.
Article Synopsis
- The main treatment for immune-mediated thrombotic thrombocytopenic purpura (iTTP) in children includes therapeutic plasma exchange (TPE), corticosteroids, and rituximab, while caplacizumab is used for older children and adults, but its use for those under 12 is not officially approved.
- A case study of a 7-year-old girl with iTTP showed successful treatment with caplacizumab after adjusting the dose according to her ADAMTS13 activity, leading to significant clinical improvement and full recovery without major side effects.
- The review of existing literature revealed five cases of iTTP in children under 12 treated with caplacizumab, all showing success and safety,
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!